Thank you.
I think it's important to remember that in the one instance when, despite the flaws in CAMR, it was actually made possible to get a medicine out the door, the price the generic manufacturer offered Rwanda was competitive. It was 19.5¢ per tablet, which was the same price on offer from the Indian generic manufacturers. We have to remember, as I was saying before, that although India has been an incredibly important source of supply of generic medicines—it's been the pharmacy of the poor—the Indian generic industry does not have the capacity as it is now to supply all of the generic medicines the developing world needs. The Indian generic industry is actually under some significant pressure.
I mentioned earlier, in responding to Mr. Malo, that in 2005, as a condition of being a WTO member, India changed its patent law so that it now grants patents on pharmaceutical products. So those first-line, first-generation antiretroviral drugs that have been key in putting 5.2 million people on treatment are being supplied because they come from a time when there was no patent protection in India on those medicines. The reason the price is now shooting back up for the second-line drugs we're talking about is that those are not available, for the most part, in generic form, and they won't be available easily from Indian manufacturers, because they now have the patent barriers at the Indian end of things.
So the situation for the potential competitors of Canadian generics is changing. Canadian generics can compete, in some instances. If we actually made it simpler and less costly to use this mechanism and let them actually line up multiple contracts with multiple countries at one time under one license, you could actually then achieve economies of scale that would let them bring down the prices of medicines further, because they could get their ingredients more cheaply. Their production lines would be cheaper to run per unit, so you would be more competitive.
All of these factors are in play, and it seems to me that they all point us in one direction, which is to make this thing simple and easy to use, because we'll be able to compete.